Industry News

• Novel gene expression test, PROLARIS(TM), accurately predicts prostate cancer recurrence  Myriad Genetics said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS(TM), was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
  Myriad Genetics, Inc. March 08, 2010  
• Lilly to acquire European rights to Pfizer Animal Health assets  Elanco, the animal health division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products.
  Eli Lilly and Company March 08, 2010  
• Agilent Technologies' executive vice president and CFO Adrian Dillon to leave company  Agilent Technologies announced that Adrian T. Dillon will resign his position as executive vice president, finance and administration, and CFO, effective April 1. Dillon will become chief financial and administration officer at Skype, based in Luxembourg.
  Agilent Technologies Inc. March 05, 2010  
• Scientists find new form of prion disease that damages brain arteries   NIH scientists investigating how prion diseases destroy the brain have observed a new form of the disease in mice that does not cause the sponge-like brain deterioration typically seen in prion diseases. Instead, it resembles a form of human Alzheimer's disease.
  National Institutes of Health March 05, 2010  
• Johnson & Johnson Consumer Companies unveils CYTOMIMIC(TM) Technology  Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies have discovered how to harness the power of bioelectricity to help improve skin rejuvenation.
  Johnson & Johnson March 05, 2010  
• Life Technologies, TGen and US oncology partner on groundbreaking research  Life Technologies announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.
  TGen March 05, 2010  
• Capstone Therapeutics announces compliance with Nasdaq listing rules  Capstone Therapeutics announced it received a letter on March 4, 2010 from The Nasdaq Stock Market notifying the Company that it is now in compliance with the Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market.
  Capstone Therapeutics March 05, 2010  
• ADVANCE-2 study results demonstrate investigational anticoagulant apixaban was superior  Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb and Pfizer, was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery.
  Pfizer Inc. March 04, 2010  
• FDA approves name change for heartburn drug Kapidex  The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian.
  FDA March 04, 2010  
• Edmonds Community College announces online medical device training  Edmonds Community College announced they will offer three online certificates for medical device employees and students interested in pursuing careers in the medical device field. Edmonds Community College is a member of and partner with the Medical Device Industry Education Consortium (MDIEC).
  Edmonds Community College March 04, 2010  

   (next 10 articles)